Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHN2 | P52757 | 1/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | THRB | P10828 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.65 |
| ▸ | ABCC2 | Q92887 | 2/20 | 0.65 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.53 |
| ▸ | EBP | Q15125 | 2/20 | 0.51 |
| ▸ | DHCR7 | Q9UBM7 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 4/20 | 0.51 |
| ▸ | BLM | P54132 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16562342 | 0.90 | CHN2 (0.81) | CHN2PRKCDMEN1THRBKMT2A | |
| SCHEMBL30139090 | 0.90 | CHN2 (0.81) | CHN2PRKCDMEN1THRBKMT2A | |
| SCHEMBL22275557 | 0.84 | MEN1 (0.74) | CHN2PRKCDMEN1THRBKMT2A | |
| SCHEMBL13798724 | 0.82 | CHN2 (0.70) | CHN2PRKCDMEN1THRBKMT2A | |
| SCHEMBL1103790 | 0.80 | MEN1 (0.67) | CHN2PRKCDMEN1THRBKMT2A | |
| SCHEMBL13798725 | 0.80 | MEN1 (0.67) | CHN2PRKCDMEN1THRBKMT2A | |
| SCHEMBL18751205 | 0.79 | MEN1 (0.73) | CHN2PRKCDMEN1THRBKMT2A | |
| SCHEMBL14703485 | 0.79 | MEN1 (0.73) | CHN2PRKCDMEN1THRBKMT2A | |
| SCHEMBL14706187 | 0.79 | MEN1 (0.73) | CHN2PRKCDMEN1THRBKMT2A | |
| SCHEMBL21026497 | 0.79 | CHN2 (0.65) | CHN2PRKCDMEN1THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120005877-A | SiRNA for inhibiting expression of complement factor B and application thereof | 纳肽得(青岛)生物医药有限公司 | 2025-05-16 | — | — | CN | claimed |
| US-20240366521-A1 | NANOPARTICLES AND METHODS OF USE | QANA THERAPEUTICS INC. | 2024-11-07 | — | — | US | claimed |
| WO-2024155728-A1 | NANOPARTICLES AND METHODS OF USE | QANA THERAPEUTICS INC. (US) | 2024-07-25 | — | — | WO | claimed |
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | disclosed |
| CN-120005877-A | SiRNA for inhibiting expression of complement factor B and application thereof | 纳肽得(青岛)生物医药有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20240366521-A1 | NANOPARTICLES AND METHODS OF USE | QANA THERAPEUTICS INC. | 2024-11-07 | — | — | US | disclosed |
| WO-2024155728-A1 | NANOPARTICLES AND METHODS OF USE | QANA THERAPEUTICS INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20240124889-A1 | COMPOSITIONS AND METHODS FOR THE VECTORED AUGMENTATION OF PROTEIN DESTRUCTION, EXPRESSION AND/OR REGULATION | VOYAGER THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11666589-B2 | Pivarubicin and benzarubicin compositions | PARADOX PHARMACEUTICALS INC (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220389449-A1 | COMPOSITIONS FOR THE TREATMENT OF DISEASE | VOYAGER THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| CN-115298312-A | Leucine-rich repeat kinase 2 (LRRK 2) iRNA agent compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220213219-A1 | Bruton's Tyrosine Kinase as Anti-Cancer Drug Target | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2022-07-07 | — | — | US | disclosed |
| US-11326182-B2 | Compositions for the treatment of disease | VOYAGER THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366521-A1 | NANOPARTICLES AND METHODS OF USE | CD63, CLTB, CD47 | CHN2 928/4885PRKCD 3858/4885MEN1 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.